Современная терапия неходжкинских лимфом


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Внедрение в последнее десятилетие химерного моноклонального антитела ритуксимаб в клиническую практику позволило добиться определенных успехов в лечении В-клеточных лимфом. Эффективность ритуксимаба показана как в монотерапии, так и в комбинации с химиотерапией, а также на этапе поддерживающего лечения. Дальнейшие успехи в лечении указанных заболеваний, вероятно, будут связаны с проведением риск-адаптированной терапии и комбинацией с таргетными генными ингибиторами.

Полный текст

Доступ закрыт

Об авторах

Ю. А Алексеева

ФЦСКЭ им В.А. Алмазова

кандидат медицинских наук, заведующая отделением химиотерапии онкогематологических заболеваний с блоком ТКМ Санкт-Петербург

Список литературы

  1. Fisher Ri, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin lymphoma. N Engl J Med 1993;328(14);1002-06.
  2. Hans CP1 Weisenburger DD, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103(1): 275-82.
  3. Rosenwald A, Wright G, Leroy K. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. J Experimen Med 2003;198(6):851-62.
  4. Gregory SA, Trumper L. Chemotherapy dose intensity in non-Hodgkins lymphoma: is dose intensity an emerging paradigm for better outcomes? Annals of Oncology 2005;16: 1413-24.
  5. Barlett NL, Petroni GR. Dose-escalated CHOEP for patients with diffuse lymphoma. Cancer and Leukemia Group B studies 8852 and 8854. Cancer 2001;92:207-17.
  6. Martelli N, Gherlinzoni F. Early autologous stemcell transplantation versus conventional chemotherapy as front-line therapy in high risk aggressive non-Hodgkins lymphoma; an italian multicenter randomized trial. J Clin Oncol 2003;21:1255-62.
  7. Vitolo U, Chiappella A, Angelucci E, et al. Dose-dense and high-dose chemotherapy plus Rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma at poor prognosis: a phase ii multicenter study. Haematologica 2009;94(9):1250-58.
  8. Pfreundschuh M. Therapy of diffuse large B-cell lymphomas. Eur J Cancer 45:386-87.
  9. Cunningham D, Smith P, Mouncey P, et al. R-CHOP14 versus R-CHOP21: Result of a randomized phase iii trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol 2011;29:abstract 8000.
  10. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. J Clin Oncol 2006;24(19):3121-27.
  11. Giesselbrecht C, Schmitz N, Mounier N, et al. R-iCE versus R-DHAP in relapsed patients with CD20 difuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL study. Blood (ASH Annual Meeting Abstracts) 2007;110:517.
  12. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MiPi) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558-65.
  13. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385-87.
  14. Khouri iF, Romaguera J, Kantarjian H, et al. Champlin Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16(12):3803.
  15. Ganti AK, Bierman PJ, Lynch JC, et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005; 16:618-24.
  16. Williams ME, Dreyling M, Winter J, et al. Management of Mantle Cell Lymphoma: Key Challenges and Next Steps. Clin Lymphoma Myeloma Leuk 2010;10(5):336-46.
  17. Geisler CH, Kolstad A, Laurell A, et al. Longterm progression-free survival of mantle cell lymphoma after intensive front-line immuno-chemotherapy with in vivo-purged stem cell rescue: a nonrandomized Phase II multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-93.
  18. Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011;12(4):361.
  19. Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009;84(9):553-59.
  20. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22(7):1622.
  21. Goy SH, Bernstein BS, Kahl B, et al. Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S):7512.
  22. Friedberg JW, Vose M, et al. The combination of bendamustine, bortesomibe, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807-12.
  23. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-64.
  24. Gordan LN, Grow WB, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lympho-proliferative disorders. J Clin Oncol 2005;23: 1096-102.
  25. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009; 27:1607-14.
  26. Moccia IA HP, Klasa R, Savage KJ, et al. Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance. Blood (Meeting abstracts) 2010;116:1803.
  27. Rummel MJ, Balser C, Stauch MB, et al. Bendamustine Plus Rituximab vs Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas - Final Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood (Meeting abstracts) 2010;116:856.
  28. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344-49.
  29. Rodriguez J, Conde E, Gutierrez A, et al. The results of consolidation with autologous stemcell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007;18:652-57.
  30. Feyler S, Prince HM, Pearce R, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007;40:443-50.
  31. Corradini P, Tarella C, Zallio F, et al. Longterm follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533-38.
  32. Minich SS. Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma. Ann Pharmacother 2012;46:377-83.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах